請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34340完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 莊雅惠(Ya-Hui Chuang) | |
| dc.contributor.author | You-Ru Jang | en |
| dc.contributor.author | 簡佑儒 | zh_TW |
| dc.date.accessioned | 2021-06-13T06:03:51Z | - |
| dc.date.available | 2016-10-07 | |
| dc.date.copyright | 2011-10-07 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2011-07-26 | |
| dc.identifier.citation | 1. Broide DH. 2001. Molecular and cellular mechanisms of allergic disease. Journal of Allergy and Clinical Immunology 108: S65-S71
2. Wilson DHD, Adams RJ, Tucker GR, Appleton SL, Taylor AW, Ruffin RE. 2006. Trends in asthma prevalence and population changes in South Australia, 1990-2003.: Australasian Medical Publishing 3. Kim HY, DeKruyff RH, Umetsu DT. 2010. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nature Immunology 11: 577-84 4. Holgate ST, Polosa R. 2008. Treatment strategies for allergy and asthma. Nature Review Immunology 8: 218-30 5. Van Hove CL, Maes T, Joos GF, Tournoy KG. 2008. Chronic inflammation in asthma: a contest of persistence vs resolution. Allergy 63: 1095-109 6. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. 2000. Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling. American Journal of Respiratory and Critical Care Medicine 161: 1720-45 7. Hammad H, Lambrecht BN. 2006. Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. The Journal of allergy and clinical immunology 118: 331-6 8. Shortman K, Liu Y-J. 2002. Mouse and human dendritic cell subtypes. Nature Review Immunology 2: 151-61 9. Lambrecht BN, Hammad H. 2009. Biology of Lung Dendritic Cells at the Origin of Asthma. Immunity 31: 412-24 10. Jahnsen FL, Strickland DH, Thomas JA, Tobagus IT, Napoli S, Zosky GR, Turner DJ, Sly PD, Stumbles PA, Holt PG. 2006. Accelerated Antigen Sampling and Transport by Airway Mucosal Dendritic Cells following Inhalation of a Bacterial Stimulus. The Journal of Immunology 177: 5861-7 11. Chieppa M, Rescigno M, Huang AYC, Germain RN. 2006. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. The Journal of Experimental Medicine 203: 2841-52 12. Kauffman H. 2006. Innate immune responses to environmental allergens. Clinical Reviews in Allergy and Immunology 30: 129-40 13. Kato A, Favoreto S, Avila PC, Schleimer RP. 2007. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. The Journal of Immunology 179: 1080-7 14. Kiss A, Montes M, Susarla S, Jaensson EA, Drouin SM, Wetsel RA, Yao Z, Martin R, Hamzeh N, Adelagun R, Amar S, Kheradmand F, Corry DB. 2007. A new mechanism regulating the initiation of allergic airway inflammation. The Journal of allergy and clinical immunology 120: 334-42 15. Ebeling C, Lam T, Gordon JR, Hollenberg MD, Vliagoftis H. 2007. Proteinase-activated receptor-2 promotes allergic sensitization to an inhaled antigen through a TNF-mediated pathway. The Journal of Immunology 179: 2910-7 16. Stumbles PA, Strickland DH, Pimm CL, Proksch SF, Marsh AM, McWilliam AS, Bosco A, Tobagus I, Thomas JA, Napoli S, Proudfoot AEI, Wells TNC, Holt PG. 2001. Regulation of dendritic cell recruitment into resting and inflamed airway epithelium: use of alternative chemokine receptors as a function of inducing simulus. The Journal of Immunology 167: 228-34 17. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, Waal-Malefyt Rd, Bazan F, Kastelein RA, Liu Y-J. 2002. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nature Immunology 3: 673-80 18. Lloyd CM, Hessel EM. 2010. Functions of T cells in asthma: more than just TH2 cells. Nature Review Immunology 10: 838-48 19. Cohn L, Elias JA, Chupp GL. 2004. Asthma: Mechanisms of Disease Persistence and Progression. Annual Review of Immunology 22: 789-815 20. Wills-Karp M. 1999. Immunologic basis of antigen-induced airwqy hyperresponsiveness. Annual Review of Immunology 17: 255-81 21. Brusselle GG, Kips JC, Tavernier JH, Van Der Heyden JG, Cuvelier CA, Pauwels RA, Bluethmann H. 1994. Attenuation of allergic airway inflammation in IL-4 deficient mice. Clinical & Experimental Allergy 24: 73-80 22. Sanderson C. 1992. Interleukin-5, eosinophils, and disease. Blood 79: 3101-9 23. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. 1996. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. The Journal of Experimental Medicine 183: 195-201 24. Finkelman FD, Hogan SP, Hershey GKK, Rothenberg ME, Wills-Karp M. 2010. Importance of cytokines in murine allergic airway disease and human asthma. The Journal of Immunology 184: 1663-74 25. Gould HJ, Sutton BJ. 2008. IgE in allergy and asthma today. Nature Review Immunology 8: 205-17 26. Gould HJ, Beavil RL, Vercelli D. 2000. lgE isotype determination: ε-germline gene transcription, DNA recombination and B-cell differentiation. British Medical Bulletin 56: 908-24 27. Holgate ST, Djukanović R, Casale T, Bousquet J. 2005. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clinical & Experimental Allergy 35: 408-16 28. Reber L, Da Silva CA, Frossard N. 2006. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. European Journal of Pharmacology 533: 327-40 29. Barnes PJ. 2008. Immunology of asthma and chronic obstructive pulmonary disease. Nature Review Immunology 8: 183-92 30. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CMM, Tsai M. 2005. Mast cell as 'TUNABLE' effector and immunoregulatory cells: Recent Advances. Annual Review of Immunology 23: 749-86 31. Gibson PG, Denburg J, Dolovich J, Ramsdale EH, Hargreave FE. 1989. Chronic cough: eosinophilic bronchitis without asthma. The Lancet 333: 1346-8 32. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. 2002. Mast-cell infiltration of airway smooth muscle in asthma. New England Journal of Medicine 346: 1699-705 33. Williams CMM, Galli SJ. 2000. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. The Journal of Experimental Medicine 192: 455-62 34. Barrett NA, Austen KF. 2009. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 31: 425-37 35. Akuthota P, Wang HB, Spencer LA, Weller PF. 2008. Immunoregulatory roles of eosinophils: a new look at a familiar cell. Clinical & Experimental Allergy 38: 1254-63 36. Gleich GJ, Adolphson CR. 1986. The Eosinophilic Leukocyte: Structure and Function. In Advances in Immunology, ed. KFALEH Frank J. Dixon, WU Jonathan, pp. 177-253: Academic Press 37. Rothenberg ME. 1998. Eosinophilia. New England Journal of Medicine 338: 1592-600 38. Jacoby DB, Gleich GJ, Fryer AD. 1993. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. The Journal of Clinical Investigation 91: 1314-8 39. Boyce JA, Austen KF. 2005. No audible wheezing. The Journal of Experimental Medicine 201: 1869-73 40. Mishra A, Hogan SP, Brandt EB, Wagner N, Crossman MW, Foster PS, Rothenberg ME. 2002. Enterocyte Expression of the Eotaxin and Interleukin-5 Transgenes Induces Compartmentalized Dysregulation of Eosinophil Trafficking. Journal of Biological Chemistry 277: 4406-12 41. Dent LA, Strath M, Mellor AL, Sanderson CJ. 1990. Eosinophilia in transgenic mice expressing interleukin 5. The Journal of Experimental Medicine 172: 1425-31 42. Tominaga A, Takaki S, Koyama N, Katoh S, Matsumoto R, Migita M, Hitoshi Y, Hosoya Y, Yamauchi S, Kanai Y. 1991. Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production. The Journal of Experimental Medicine 173: 429-37 43. Lee JJ, McGarry MP, Farmer SC, Denzler KL, Larson KA, Carrigan PE, Brenneise IE, Horton MA, Haczku A, Gelfand EW, Leikauf GD, Lee NA. 1997. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. The Journal of Experimental Medicine 185: 2143-56 44. Justice JP, Borchers MT, Crosby JR, Hines EM, Shen HH, Ochkur SI, McGarry MP, Lee NA, Lee JJ. 2003. Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. American Journal of Physiology - Lung Cellular and Molecular Physiology 284: L169-L78 45. Leckie MJ, Brinke At, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ. 2000. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-respons?veness, and the late asthmatic response. The Lancet 356: 2144-8 46. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB. 2003. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. The Journal of Clinical Investigation 112: 1029-36 47. Boushey HA. 1982. Bronchial hyperreactivity to sulfur dioxide: physiologic and political implications. Journal of Allergy and Clinical Immunology 69: 335-8 48. Obenauer JC, Denson J, Mehta PK, Su X, Mukatira S, Finkelstein DB, Xu X, Wang J, Ma J, Fan Y, Rakestraw KM, Webster RG, Hoffmann E, Krauss S, Zheng J, Zhang Z, Naeve CW. 2006. Large-scale sequence analysis of avian influenza isolates. Science 311: 1576-80 49. Zambon MC. 1999. Epidemiology and pathogenesis of influenza. Journal of Antimicrobial Chemotherapy 44: 3-9 50. Both GW, Sleigh MJ, Cox NJ, Kendal AP. 1983. Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. The Journal of Virology 48: 52-60 51. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, Fouchier RAM. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305: 371-6 52. Plotkin JB, Dushoff J, Levin SA. 2002. Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus. Proceedings of the National Academy of Sciences 99: 6263-8 53. Koelle K, Cobey S, Grenfell B, Pascual M. 2006. Epochal Evolution Shapes the Phylodynamics of Interpandemic Influenza A (H3N2) in Humans. Science 314: 1898-903 54. 2001. Emergence of influenza A viruses. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 356: 1817-28 55. Potter CW. 2001. A history of influenza. Journal of Applied Microbiology 91: 572-9 56. Carrat F, Flahault A. 2007. Influenza vaccine: The challenge of antigenic drift. Vaccine 25: 6852-62 57. Glezen WP. 1996. Emerging Infections: Pandemic Influenza. Epidemiologic Reviews 18: 64-76 58. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. 2005. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. The Lancet 366: 1165-74 59. Ellebedy AH, Webby RJ. 2009. Influenza vaccines. Vaccine 27: D65-D8 60. Bresson J-L, Perronne C, Launay O, Gerdil C, Saville M, Wood J, H?schler K, Zambon MC. 2006. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. The Lancet 367: 1657-64 61. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New England Journal of Medicine 354: 1343-51 62. Wareing MD, Tannock GA. 2001. Live attenuated vaccines against influenza; an historical review. Vaccine 19: 3320-30 63. Justewicz D, Morin M, Robinson H, Webster R. 1995. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. The Journal of Virology 69: 7712-7 64. Clements ML, Betts RF, Tierney EL, Murphy BR. 1986. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. Journal of Clinical Microbiology 23: 73-6 65. Edwards KM, Dupont WD, Westrich MK, Walton DP, Jr., Palmer PS, Wright PF. 1994. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. The Journal of Infectious Diseases 169: 68-76 66. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. 2006. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. New England Journal of Medicine 355: 2513-22 67. Erhart LM, Rangel MC, Lu P-J, Singleton JA. 2004. Prevalence and characteristics of children at increased risk for complications from influenza, United States, 2000. The Journal of Pediatrics 144: 191-5 68. O'Brien MA, Uyeki TM, Shay DK, Thompson WW, Kleinman K, McAdam A, Yu X-J, Platt R, Lieu TA. 2004. Incidence of Outpatient Visits and Hospitalizations Related to Influenza in Infants and Young Children. Pediatrics 113: 585-93 69. 2001. The safety of inactivated influenza vaccine in adults and children with Asthma. New England Journal of Medicine 345: 1529-36 70. Karl GN, Jonathan SN-V-T, Ala'eldin HA, Martin JW, Jane L, Jon A, James HC, Philip E, Noemi ME, Bruce JH, James CGP, Richard FW, Roger JW, Mark AW. 1998. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. The Lancet 351: 326-31 71. Georas SN, Guo J, De Fanis U, Casolaro V. 2005. T-helper cell type-2 regulation in allergic disease. European Respiratory Journal 26: 1119-37 72. Singh M, O'Hagan D. 1999. Advances in vaccine adjuvants. Nature Biotechnology 17: 1075-81 73. Finkelman FD, Holmes J, Katona IM, Urban JF, Beckmann MP, Park LS, Schooley KA, Coffman RL, Mosmann TR, Paul WE. 1990. Lymphokine control of in vivo immunoglobulin isotype selection. Annual Review of Immunology 8: 303-33 74. Coffman RL, Seymour BWP, Lebman DA, Hiraki DD, Christiansen JA, Shrader B, Cherwinski HM, Savelkoul HFJ, Finkelman FD, Bond MW, Mosmann TR. 1988. The role of helper T cell products in mouse B cell differentiation and Isotype Regulation. Immunological Reviews 102: 5-28 75. Chirkova T, Petukhova G, Korenkov D, Naikhin A, Rudenko L. 2008. Immunization with live influenza viruses in an experimental model of allergic bronchial asthma: infection and vaccination. Influenza and Other Respiratory Viruses 2: 165-74 76. Minne A, Huaux F, Jaworska J, Rha R-D, Hamelmann E, Vanbever R. 2008. Safety evaluation of pulmonary influenza vaccination in healthy and 'asthmatic' mice. Vaccine 26: 2360-8 77. Strachan DP. 1989. Hay fever, hygiene, and household size. British Medical Journal 299: 1259-60 78. Wang, Rook. 1998. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 93: 307-13 79. Minne A, Jaworska J, Gerhold K, Ahrens B, Avagyan A, Vanbever R, Matricardi PM, Schmidt AC, Hamelmann E. 2007. Intranasal delivery of whole influenza vaccine prevents subsequent allergen-induced sensitization and airway hyper-reactivity in mice. Clinical & Experimental Allergy 37: 1250-8 80. Elser B, Lohoff M, Kock S, Giaisi M, Kirchhoff S, Krammer PH, Li-Weber M. 2002. IFN-[gamma] Represses IL-4 Expression via IRF-1 and IRF-2. Immunity 17: 703-12 81. Diehl S, Anguita J, Hoffmeyer A, Zapton T, Ihle JN, Fikrig E, Rincón M. 2000. Inhibition of Th1 Differentiation by IL-6 Is Mediated by SOCS1. Immunity 13: 805-15 82. Diehl S, Chow C-W, Weiss L, Palmetshofer A, Twardzik T, Rounds L, Serfling E, Davis RJ, Anguita J, Rincón M. 2002. Induction of NFATc2 Expression by Interleukin 6 Promotes T Helper Type 2 Differentiation. The Journal of Experimental Medicine 196: 39-49 83. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proceedings of the National Academy of Sciences of the United States of America 101: 5598-603 84. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. 2004. Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA. Science 303: 1529-31 85. Wang X, Xu W, Mohapatra S, Kong X, Li X, Lockey R, Mohapatra S. 2008. Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genetic Vaccines and Therapy 6: 7 86. Du Q, Zhou L-F, Chen Z, Gu X-Y, Huang M, Yin K-S. 2009. Imiquimod, a toll-like receptor 7 ligand, inhibits airway remodelling in a murine model of chronic asthma. Clinical and Experimental Pharmacology and Physiology 36: 43-8 87. Xirakia C, Koltsida O, Stavropoulos A, Thanassopoulou A, Aidinis V, Sideras P, Andreakos E. 2010. Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. American Journal of Respiratory and Critical Care Medicine 181: 1207-16 88. David HB. 2001. Molecular and cellular mechanisms of allergic disease. The Journal of allergy and clinical immunology 108: S65-S71 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34340 | - |
| dc.description.abstract | 過敏性氣喘是人體對過敏原產生過度TH2反應的一種疾病。病人呼吸道有長期的慢性發炎，當吸入過敏原時會產生急性反應，如平滑肌收縮、黏液分泌等，稱為呼吸道過度反應，使呼吸道狹窄，病人因此不易吸入空氣而導致咳嗽、喘鳴等典型氣喘病徵。流感病毒是感染呼吸道上皮細胞的一種RNA病毒，每年會造成季節性流行，但可藉由施打疫苗以避免病毒感染。氣喘病人是感染流感病毒後引發重症的高危險群，然而，疫苗主要使人體產生抗病毒的TH1免疫反應，可能與氣喘病人的TH2免疫反應互相拮抗，但也可能使病人呼吸道發炎反應增強。目前仍沒有詳細研究流感疫苗產生的免疫反應會對氣喘病人造成何種影響，本研究探討去活性流感病毒疫苗對於OVA所引起之小鼠氣喘之影響。
研究結果顯示，流感病毒使用紫外光照射去活性後，打入小鼠體內可以使小鼠產生抗病毒抗體。接著將去活性流感病毒疫苗施打於OVA致敏之小鼠，在最後一次施打疫苗後兩天、五天以及七天給予OVA刺激，評估疫苗所引起之先天性及後天性免疫反應是否對氣喘小鼠造成影響。結果發現疫苗的施打並不影響呼吸道發炎反應，血清中OVA特異性IgE濃度沒有改變，肺臟沖洗液之發炎細胞的種類、數目以及細胞激素濃度亦沒有顯著的改變。然而，在施打疫苗後七天給予OVA 刺激的實驗中，施打較高劑量疫苗的氣喘小鼠，其肺泡沖洗液中的IL-4以及IL-6明顯低於不施打疫苗的控制組。 以上結果顯示，施打病毒後，即使小鼠產生強烈的抗病毒抗體反應，也不會使氣喘相關之免疫反應加劇，反而可能與TH2免疫反應拮抗，而抑制與氣喘相關之細胞激素的產生。因此，未來除了以流感病毒感染氣喘小鼠，探討疫苗在其體內的保護力，也可進一步探討疫苗與TH2免疫反應拮抗的相關機轉。 | zh_TW |
| dc.description.abstract | Asthma is a heterogeneous disorder characterized by airway inflammation and airway hyper-reactivity (AHR). The symptoms of asthma are recurrent wheezing, coughing and shortness of breath. Allergic asthma is the most common type of asthma. Allergen-specific TH2 cells, eosinophils, and the production of allergen-specific IgE are the cardinal features of allergic asthma. Influenza virus is a single strand segmented RNA virus mainly infected airway epithelial cells. Every year influenza virus can cause seasonal epidemics and results in many hospitalizations and deaths. Asthma patients are high risk group for serious disease from influenza infection. Fortunately, flu vaccine can effectively prevent influenza infection, so many countries recommend asthma patients to receive flu vaccination. However, whether influenza vaccine is safe for asthma patients is still unclear. The aim of this study is to evaluate the safety and impact of influenza vaccine on allergic asthma in an OVA-immunized mouse model.
To investigate the impact of different vaccine-induced immune response, innate and adaptive immunity, OVA-sensitized mice were challenged at different time points after vaccination. The results showed that intramuscular vaccination induces strong anti-virus immune response but not inflammatory response in asthma mice of all groups. Furthermore, the characteristics of asthma such as OVA specific IgE, cytokines, cell numbers and population in broncho-alveolar lavage fluid (BALF) were not increased after vaccination. Moreover, we found that some of these phenotypes, IL-4 and IL-6, were significantly decreased. Our data demonstrated that vaccination doesn’t exacerbate asthmatic phenotypes in mice. In contrast, TH1 biased vaccine response may somehow suppress TH2 immune response in asthma. In the future, the protective effect of flu vaccine in asthma mouse and the relationship between different immune responses induced by vaccine and asthma, respectively, will be investigated. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T06:03:51Z (GMT). No. of bitstreams: 1 ntu-100-R98424010-1.pdf: 4743710 bytes, checksum: 8fb36a16267d08394847bb28f7af3c86 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | 致謝 i
摘要 ii Abstract iii 縮寫對照表 iv 第一章 研究背景 1 1.1氣喘(asthma) 1 1.1.1過敏性氣喘(allergic asthma) 1 1.1.2發炎反應(chronic inflammatory response) 1 1.1.2.1樹突狀細胞(dendritic cells, DCs) 2 1.1.2.2呼吸道上皮細胞(airway epithelial cells) 2 1.1.2.3 T淋巴球(T lymphocytes) 3 1.1.2.4 B淋巴球(B lymphocytes) 3 1.1.2.5肥大細胞(mast cells) 3 1.1.2.6嗜酸性球(eosinophils) 4 1.1.3呼吸道過度反應(airway hyperresponsiveness；AHR) 5 1.2流感病毒(Influenza virus) 6 1.2.1抗原微變(antigen drift) 6 1.2.2抗原移變(antigen shift) 6 1.2.3流感疫苗(Influenza vaccine) 7 1.2.3.1去活性流感疫苗(inactivated influenza vaccines, IIV) 7 1.2.3.2減毒流感疫苗(live attenuated influenza vaccines, LAIV) 8 1.3流感疫苗與氣喘 9 1.4研究目的 9 第二章 實驗材料與方法 10 2.1實驗用小鼠 10 2.2氣喘動物模式 10 2.2.1 Sensitization 10 2.2.2 Challenge 10 2.3 Influenza A virus (A/Puerto Rico/8/34 (H1N1)) 11 2.3.1 病毒培養 11 2.3.2 病毒純化 11 2.3.3 病毒定量 11 2.3.4 病毒去活性 12 2.4 施打去活性PR8病毒於BALB/c小鼠 12 2.5 小鼠肺臟沖洗液之收集與處理 12 2.6 小鼠肺臟沖洗液之細胞離心及染色 13 2.7 小鼠肺臟沖洗液細胞分類 13 2.8 以ELISA偵測OVA特異性IgE 13 2.9 以ELISA偵測PR8特異性IgG 14 2.10 以ELISA偵測PR8特異性IgG2a 14 2.11 以ELISA偵測mouse IL-4、IL-5、IL-13、Eotaxin、TNF-a 15 2.12 以ELISA偵測mouse IFN-g 15 2.13 以BCA protein assay 偵測蛋白質濃度 15 2.14 肺臟病理切片 16 2.14.2 肺臟病理切片判讀 16 2.15 繪圖與統計分析 16 第三章 結果 17 3.1 施打去活性病毒使小鼠產生抗病毒反應。 17 3.2 使用不同施打路徑注射病毒，觀察抗體反應之差異。 17 3.3 使用肌肉注射施打疫苗於OVA致敏小鼠。 18 3.4 疫苗施打後二天以OVA刺激呼吸道、犧牲OVA致敏小鼠。 18 3.4.1血清中OVA特異性IgE。 18 3.4.2肺臟內細胞激素。 18 3.4.3發炎指標。 19 3.4.4肺臟內浸潤細胞。 19 3.4.5肺臟病理切片。 20 3.5 疫苗施打後五天以OVA刺激呼吸道、犧牲OVA致敏小鼠。 20 3.5.1血清中OVA特異性IgE。 20 3.5.2肺臟內細胞激素。 20 3.5.3發炎指標。 21 3.5.4肺臟內浸潤細胞。 21 3.5.5肺臟病理切片。 21 3.6 疫苗施打後七天以OVA刺激呼吸道、犧牲OVA致敏小鼠。 22 3.6.1血清中OVA特異性IgE。 22 3.6.2肺臟內細胞激素。 22 3.6.3發炎指標。 22 3.6.4肺臟內浸潤細胞。 23 3.6.5肺臟病理切片。 23 第四章 討論 24 圖 28 參考文獻 53 附錄 65 | |
| dc.language.iso | zh-TW | |
| dc.subject | 呼吸道發炎反應 | zh_TW |
| dc.subject | 流感病毒 | zh_TW |
| dc.subject | 氣喘 | zh_TW |
| dc.subject | 肺臟沖洗液 | zh_TW |
| dc.subject | 流感疫苗 | zh_TW |
| dc.subject | flu vaccine | en |
| dc.subject | asthma | en |
| dc.subject | airway inflammation | en |
| dc.subject | broncho-alveolar lavage fluid (BALF) | en |
| dc.subject | influenza virus | en |
| dc.title | 以OVA致敏小鼠模式評估去活性流感病毒疫苗對過敏性氣喘之影響 | zh_TW |
| dc.title | Evaluation of Inactivated Influenza Vaccination on Allergic Asthma in an OVA-immunized Mouse Model | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 99-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 江伯倫,張淑媛 | |
| dc.subject.keyword | 氣喘,呼吸道發炎反應,肺臟沖洗液,流感病毒,流感疫苗, | zh_TW |
| dc.subject.keyword | asthma,airway inflammation,broncho-alveolar lavage fluid (BALF),influenza virus,flu vaccine, | en |
| dc.relation.page | 69 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2011-07-26 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
| 顯示於系所單位： | 醫學檢驗暨生物技術學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 未授權公開取用 | 4.63 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。